Posted: June 29, 2015
TEC Edmonton’s Technology Management team offers expert advice on intellectual property matters which often lead to new patents, licensing agreements and company spin-offs.
Small Molecule Inhibitors of Polynucleotide Kinase/Phosphatase, Poly(ADP-RIBOSE) Polymerase and Uses Thereof
U.S. Patent No. 9,040,551, issued May 26th 2015
This patent covers new inhibitors of polynucelotide kinase/phosphatase (PNKP), a DNA repair enzyme and emerging cancer therapy target. The inventors, Drs. Michael Weinfeld, Gary Freschauf, Feridoun Karimi-Busheri and Todd Mereniuk (UA Oncology), and Dr. Dennis Hall (UA Chemistry) are building on their extensive expertise with PNKP to design and test a series of compounds that will make cancer cells more sensitive to chemo and radiation therapy.
Their work has received support from the Canadian Institutes of Health Research, the Centre for Drug Research and Development (CDRD, Vancouver BC) and the Alberta Cancer Foundation.
Two-and Three-Terminal Molecular Electronic Devices with Ballistic Electron Transport
U.S. Patent No. 9,023,812, issued May 5, 2015
Dr. Richard McCreery from the University of Alberta’s Department of Chemistry received an issued U.S. patent describing a molecular electronic junction that permits rapid, non-resistive transport. The operating principle is based on tunneling and ballistic transport, thus permitting high speed, low power consumption and minimal heat generation.
These devices may provide smaller and more efficient alternatives to the semiconductor industry, specifically in computers and display devices, among others.
Methods for Producing Fuels and Solvents Substantially Free of Fatty Acids
U.S. patent No. 8,975,457, issued March 10, 2015
Dr. David Bressler of the University of Alberta’s Department of Agricultural, Food and Nutritional Science received a patent describing a new biorefining technique to purify fuels produced from agricultural waste materials by pyrolysis (heating without oxygen). This purification process separates fuels from any remaining feedstock to produce high quality biofuels that meet industry and regulatory standards. The technology can also recover high value co-products if desired and is part of a second family of patents related to the pyrolysis process.
This technology is currently licensed to Forge Hydrocarbons Corporation.
A University of Alberta technology developed by Dr. Diane Taylor has been sublicensed by licensee Ratiopharm to Glycom, a Denmark-based company.
The licensed technology relates to α1,2-fucosyltransferase proteins originally isolated from the human gut pathogen Helicobacter pylori and useful for the enzymatic production of 2’-fucosyllactose. Glycom will initially develop the technology to produce 2’-fucosyllactose, a sugar abundant in human breast milk, for use in infant formula manufacturing.
TB/HIV Research Foundation (THRF)
TEC Edmonton has successfully negotiated an Inter-Institutional Agreement between the University of Alberta and the TB/HIV Research Foundation (THRF), a non-profit organization in Thailand.
Through a collaborative research project of the Alberta Innovates Centre for Machine Learning, funded by Alberta Innovates Technology Futures, Dr. Yutaka Yasui from the School of Public Health, University of Alberta, and researchers from THRF developed a novel software algorithm for automated serial image analysis along with an inexpensive and effective machine for detection of the pathogen Mycobacterium tuberculosis. M. tuberculosis is the causative agent of tuberculosis (TB), which remains a major global health concern.
In order to make the technology readily available to individuals in endemic regions, this agreement grants THRF a royalty-free license to commercialize the technology in Thailand and other TB high-burden countries.